Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

124.13 -1.71 (-1.36%)
Streaming Delayed Price Updated: 3:15 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
From Gilead Sciences, Inc.
Via Business Wire
News headline image
GBK Brand Bar and Meals on Me Host the Official Backstage Lounge at the 40th Annual Rock & Roll Hall of Fame Induction Ceremony Rehearsals
November 10, 2025 -- During rehearsals leading up to the Induction Ceremony, GBK welcomed some of the world's biggest musicians from legendary icons to today's top superstars. 
Via 24-7 Press Release
News headline image
Gilead Provides Update on Phase 3 ASCENT-07 Study
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces Third Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Jerry Pinkas Earns Certified Probate Specialist Designation, Elevating Compassionate Real Estate Expertise for South Carolina Families
Via Get News
News headline image
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Cumberland First in Families to Host 2nd Annual Mister & Miss FIFNC Pageant
Via Get News
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at LSX World Congress 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
2024 R&D Spending and Intensity Benchmarks
Via PRLog
Topics Supply Chain
News headline image
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
From Gilead Sciences, Inc.
Via Business Wire
News headline image
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
NAFA Publishes New Fleet Safety Guidebook Aimed at Developing Safety-First Culture in all Organizations
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
News headline image
Gilead Sciences Announces Second Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.